Gain actionable strategies for embedding AI and large language models into portfolio decision making, accelerating timelines while ensuring data quality and compliance
Developing a mechanistic model of IVT to include nucleation and growth of magnesium pyrophosphate crystals and subsequent agglomeration of crystals and DNA
Nathan Stover
Engineer
BioCurie
Hear cross-functional perspectives on successfully implementing AI across process development teams, from aligning with quality, IT, and manufacturing to overcoming cultural and technical barriers, with a focus on driving operational efficiency and long-term value
Justin Byers
Founder and Chief Executive Officer
Axio BioPharma
Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.
Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.
With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.
Shruti Vij
Associate Director, Data Analytics & Modeling
(Former) Takeda
Dana Filioti
Associate Director, CMC Scientific Architecture, Development Sciences Data & Digital Strategy
AbbVie
Axio BioPharma
Website: https://www.axiobiopharma.com/
Axio BioPharma is an AI-driven biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Headquartered in Madison, WI, Axio combines high-throughput production with proprietary machine learning to predict optimal scalable manufacturing processes in hours - not years. By accelerating development timelines and reducing costs, Axio enables biopharma innovators to bring life-saving therapies to market faster and more efficiently. With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio supports a wide range of partners across research, diagnostics, and therapeutics with scalable, U.S.-based production and data-enhanced process design.
- How to mitigate inappropriate drug use and dosing risk, leveraging mechanisms like Pre-Approval Information Exchange (PIE) and PDUFA timelines to shape understanding of indication, value, and safety.
- How to engage payers as early as phase 2 to build trust and tailor future value-based contracts, launching with outcomes-driven frameworks to support access and reimbursement.
Innovation and Investment
Healthcare Costs and Outcomes
Jim Kenney
Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care
Jim Kenney
Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care
- Elucidating how researchers are using menstrual effluent to track fertility, inflammation, and disease.
- Consumer Adoption & Clinical Validation – The path to making menstrual-based diagnostics a mainstream health tool.
- Investment & Industry Growth – The market potential of menstrual-based biomarkers in diagnostics and therapeutics.
Reproductive Health
- Equip teams with AI tools that capture process knowledge and simulate scale-up scenarios, reducing tech transfer timelines and improving first-batch success rates - critical for aligning R&D, MSAT, and manufacturing expectations early.
- Explore how ML-enabled real-time control systems and continuous process verification improve yield predictability, reduce rework, and enable faster release - offering a direct line of sight to cost savings and product quality gains.
Preeya Boppana
Director of MS&T Analytics
AstraZeneca
Victoria Nichols
Senior Project Director, Free the Pill
Ibis Reproductive Health